Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

The British Journal of Dermatology
Craig L LeonardiMartin M Okun

Abstract

The clinical utility of increasing to weekly adalimumab therapy in patients with psoriasis with inadequate response to every other week (eow) dosing is unknown. (i) To determine the effectiveness of escalating adalimumab dosage from 40 mg eow to 40 mg weekly in patients with < PASI 50 response following ≥ 24 weeks treatment. (ii) To identify retrospectively characteristics of patients likely to benefit from dose escalation using classification and regression tree analysis. (iii) To assess cost implications for allowing dose escalation from the private payers' perspective. Patients with moderate-to-severe psoriasis who had received blinded adalimumab 40 mg eow or placebo in antecedent phase II/III studies could enrol in an open-label extension (OLE) and initially receive open-label adalimumab 40 mg eow (EOW population). On/after week 24 (OLE), patients with < PASI 50 response relative to baseline of antecedent study could increase to 40 mg weekly. The dosage escalation population continued on weekly dosing until achieving PASI 75 response, then resumed eow dosing. Study visits were 6/12 weeks after dosage escalation, and every 12 weeks thereafter. The percentage of patients who achieved PASI 75 response following dosage escalati...Continue Reading

References

Dec 4, 2003·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·Stephenie C LemonWilliam Rakowski
Sep 25, 2004·Journal of the American Academy of Dermatology·Richard G Langley, Charles N Ellis
Jun 19, 2007·Journal of the American Academy of Dermatology·Marina PapoutsakiSergio Chimenti
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Jan 12, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Dennis A RevickiMartin Kaul
Jan 28, 2009·American Journal of Clinical Dermatology·Katherine F Croom, Paul L McCormack
Jul 4, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·C L Martyn-SimmonsJ N W N Barker
Sep 22, 2010·Archives of Dermatological Research·U MrowietzN Yawalkar

❮ Previous
Next ❯

Citations

Apr 18, 2015·The Journal of Dermatological Treatment·Jose-Manuel CarrascosaUNKNOWN BIOBADADERM Study Group
Feb 4, 2016·The Journal of Dermatological Treatment·Tian Hao ZhuTina Bhutani
Oct 29, 2013·Expert Opinion on Biological Therapy·Bobbak MansouriAlan Menter
Jun 30, 2015·The Journal of Dermatology·Akihiko AsahinaHidemi Nakagawa
Jul 25, 2017·International Journal of Dermatology·Martin Havmose, Simon Francis Thomsen
Nov 4, 2017·The Journal of Dermatological Treatment·G CarreteroUNKNOWN from the Spanish Group of Psoriasis
Mar 11, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·R GniadeckiH D Teixeira
Sep 22, 2018·Dermatologic Therapy·Arianna ZangrilliLuca Bianchi
Jan 31, 2018·American Journal of Clinical Dermatology·Caitriona RyanBarbara A Hendrickson
Apr 4, 2020·Dermatologic Therapy·Javier Sabater-AbadEnrique Gimeno-Carpio
May 15, 2020·Ocular Immunology and Inflammation·Paulina LibermanJennifer E Thorne
May 3, 2020·Dermatologic Therapy·Ayman AbdelmaksoudMichelangelo Vestita
Aug 5, 2017·The Journal of Dermatological Treatment·Sara MazzilliLuca Bianchi
Jul 24, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Steven R FeldmanUsha G Mallya
Jul 25, 2017·Journal of Cutaneous Medicine and Surgery·Jennifer Beecker, Jiyeh Joo
Mar 6, 2021·Dermatologic Therapy·Meltem Turkmen, Sinan Dogan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.